Antisense Drug Can Safely and Effectively Reduce Elevated Lipoprotein(a)

November 14, 2018

Researchers aimed to find the optimal dose and regimen of AKCEA-APO(a)-LRX injected subcutaneously for further clinical development.

Can Omega-3 Help Reduce MACE in High Risk Patients With Hypertriglyceridemia?

November 13, 2018

In high-risk patients with mild hypertriglyceridemia, omega-3 fatty acids improved triglyceride levels and reduced major adverse cardiovascular events, according to a new meta-analysis.

AHA/ACC Release Updated Guidelines for Cholesterol Management

November 12, 2018

Updated cholesterol guidelines offer more personalized cardiovascular disease risk assessment.

Statin-Induced Musculoskeletal AEs and Timing of Concurrent Tx Examined

By November 08, 2018

The data showed MAEs onset was significantly faster with atorvastatin and rosuvastatin compared with simvastatin; a comparison with other statins could not be established due to the small number of cases identified.

Nonadherence, Discontinuation of Statins High in 1st Year of Rx

November 07, 2018

The likelihoods of nonadherence and discontinuation were increased in association with diabetes, while hypertension, angina, and congestive heart failure correlated with a reduced likelihood of nonadherence and discontinuation.

Repatha Price Cut in an Effort to Reduce Patient Out-of-Pocket Costs

By October 25, 2018

Repatha is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

PCSK9 Inhibitor Tolerability Examined in Patients With Self-Reported Statin Intolerance

By October 17, 2018

The study utilized patient-reported side effects to determine the tolerability of the PCSK9 inhibitors evolocumab and alirocumab.

Genetic Testing Recommended for Familial Hypercholesterolemia

September 14, 2018

Specifically, the panel recommends that testing include the genes encoding the low-density lipoprotein receptor, apolipoprotein B, and proprotein convertase subtilisin/kexin 9. Depending on patient phenotype, other genes may also need to be considered for analysis.

FDA to Review Praluent as Potential Treatment to Reduce Risk of MACE

By September 12, 2018

The sBLA is supported by data from the Phase 3 ODYSSEY OUTCOMES trial which included 18,924 patients who had experienced an acute coronary syndrome (ACS) in the previous 12 months.

Widespread Statin Use Not Recommended in Old, Very Old Populations

September 06, 2018

No benefit in healthy elderly patients; protective effect limited to those with type 2 DM aged 75 to 84

FDA Issues CRL Rejecting Waylivra Approval for Familial Chylomicronemia Syndrome

By August 28, 2018

"We are extremely disappointed with the FDA's decision. We continue to feel strongly that Waylivra demonstrates a favorable benefit/risk profile in people with FCS," said Akcea CEO, Paula Soteropoulos.

Praluent Labeling Updated With Dosing for HeFH Patients Undergoing LDL Apheresis

By August 24, 2018

The dosing recommendation was based on data from a double-blind, placebo-controlled study conducted in 62 patients with HeFH undergoing LDL apheresis.

PCP Statin Prescribing Up With Automated Patient Dashboard

August 09, 2018

There was a significant increase in statin prescribing in the active choice with peer comparison arm compared with usual care.

Certain Statins May Be Associated With Deficits in Cognition, Memory

By July 26, 2018

Given the lack of differences seen via the NIS, the authors suggested that subjective questionnaires may not be a trustworthy method to assess possible statin-associated cognitive deficits.

Idaho Pharmacists Able to Prescribe Meds for Several Conditions on July 1

By June 27, 2018

The new rule allows pharmacists to prescribe medications for cold sores, seasonal influenza, strep throat, and urinary tract infections, as well as statins for patients with diabetes.

Some Evidence Mobile Health Interventions Can Lower CVD Risk

June 08, 2018

mHealth programs generally improve overall cardiovascular disease risk, at least in the short term

Revised Equation May Improve Accuracy of Cardiovascular Disease Risk Estimates

By June 06, 2018

Multiple studies have indicated that the 2013 PCEs - published by the American College of Cardiology/American Heart Association Task Force on Practice Guidelines - substantially misestimated CVD risk.

LDL-C Reduction Examined With Different Evolocumab Dosing Regimens

By June 01, 2018

For this study, researchers investigated the pharmacodynamics of evolocumab in two Phase 2 placebo-controlled studies (MENDEL and LAPLACE-TIMI 57) in order to determine which dosing regimens provided the most consistent LDL-C reduction.

Acute Kidney Injury in Hospital Ups Risk of Later Heart Failure

May 18, 2018

AKI was independently associated with higher rates of the composite outcome of hospitalization for heart failure and atherosclerotic events 1-year post-discharge.

FDA Committee in Favor of Waylivra for Rare Metabolic Lipid Disorder

By May 11, 2018

Antisense technology refers to the use of synthetic nucleic acid sequences to interrupt specific protein production by targeting the corresponding messenger RNA that encodes that protein.

Zypitamag Now Available for Primary Hyperlipidemia, Mixed Dyslipidemia

By May 01, 2018

Doses of Zypitamag >4mg once daily were associated with an increased risk for severe myopathy in premarketing clinical studies, therefore dosing should not exceed 4mg once daily.

Women Less Likely to Fill Post-MI Statin Prescription

April 17, 2018

Women were less likely to fill a high-intensity statin than men overall, among those with no prior statin use, among those taking low/moderate-intensity statins prior to MI, and among those taking high-intensity statins prior to their MI.

Workplace Noise Exposure Affects Cardiovascular Risk Factors

April 12, 2018

High BP, elevated cholesterol, hearing problems more common among workers exposed to loud noise

Metformin Use Linked to Reduced Risk of Statin-Associated Muscle Pain

By March 27, 2018

Statin-associated muscle pain can hinder medication adherence which could potentially lead to an increased risk of cardiovascular events.

Only Half of Adults With Familial Hypercholesterolemia on Statins

March 26, 2018

Among adults with definite/probable FH or severe dyslipidemia, the frequency of cholesterol screening and awareness was high (>80%); statin use was uniformly low among adults with definite/probable FH and with severe dyslipidemia (52.3 and 37.6%, respectively).

Can Omega-6 Fatty Acids Protect Against Premature Death, CV Disease?

By March 19, 2018

After classifying patients into 5 groups based on their blood linoleic level, the researchers found a 43% reduced risk of premature death among those with the highest level when compared with the group with the lowest level (adjusted hazard ratio [HR] 0.57, 95% CI: 0.46, 0.71; P<0.00).

Ticagrelor and clopidogrel have similar major bleeding rates following thrombolytic therapy

March 19, 2018

Use of ticagrelor resulted in similar rates of major bleeding compared to clopidogrel in patients with ST elevation myocardial infarction treated with thrombolysis.

Icosapent Ethyl Significantly Lowers Triglycerides Without Raising LDL-C

By March 14, 2018

The ANCHOR study was not designed to determine effects on hsCRP or CV events.

Suboptimal LDL-C in FH Patient Despite Use of Three Cholesterol-Lowering Meds

By March 13, 2018

Some FH patients may have suboptimal LCL-C despite treatment with PCSK9 inhibitors, statins and ezetimibe.

Alirocumab Tied to Reduced Risk of CV Events, Death in High-Risk Patients

By March 12, 2018

The ODYSSEY Outcomes trial (N=18,924) evaluated the effect of alirocumab on the occurrence of MACE in patients who had an ACS between 1-12 months prior to trial enrollment, and who were already taking maximally-tolerated statins (atorvastatin or rosuvastatin).